BioSpace News Archive

Drug Development

Intercept Pharma Is One Step Closer to Filing for Approval of First NASH Treatment

Intercept Pharma plans to seek regulatory approval in the U.S. and Europe in the second half of this year.

February 19, 2019

·

2 min read

·

Alex Keown

Deals

Two Pharma Companies File Chapter 11 Bankruptcy

The season surrounding Valentine’s Day brings out the love in many people, but for two pharma companies, this year was a year of heartbreak. California-based Aradigm Corporation and New Jersey-based Immune Pharmaceuticals both filed Chapter 11.

February 19, 2019

·

2 min read

·

Alex Keown

5 Health Mistakes You’re Probably Making at Work

The average American spends around 90,000 hours at work, according to Business Insider. And for many people, a large portion of those hours are spend engaging in unhealthy habits that can have serious consequences to their overall health, well-being, productivity, and happiness levels.

February 19, 2019

·

3 min read

·

Editorial Staff

Deals

Deloitte Predicts Pharma Growth Driven by Orphan Disease Drugs and External Deals

Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.

February 19, 2019

·

3 min read

·

Alex Keown

A Novo Nordisk flag flies in the wind/Courtesy jor

FDA

Novo Nordisk Snags FDA Approval for Hemophilia A Treatment

On Tuesday, Novo Nordisk said the FDA approved its Biologics License Application for Esperoct (turoctocog alfa pegol) formerly known as N8-GP, for the treatment of children and adults with hemophilia A.

February 19, 2019

·

2 min read

·

Alex Keown

Business

Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

Planegg/Munich, Germany, February 19, 2019 Simon Moroney, CEO and co-founder of MorphoSys AG, informed the Company’s Supervisory Board that he has decided not to renew his contract as a member of the company’s Management Board.

February 19, 2019

·

4 min read

Business

New Addition to AgriMetis® Scientific Advisory Board Enhances Powerhouse in Research & Development

AgriMetis, LLC, is pleased to announce Dr. Adrian Percy joined the scientific advisory board (SAB) on February 1, 2019.

February 19, 2019

·

3 min read

Business

Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

Strong Launch Continues With More than 550 Patients on Reimbursed Commercial Crysvita® (burosumab) Therapy in the United States at End of 4th Quarter 2018, 80 Percent Increase Versus End of 3rd Quarter

February 19, 2019

·

11 min read

Business

Teva Eyes 25 Percent of the $750 Million EpiPen Market by Year’s End

Teva Pharmaceuticals is expecting big things from its generic EpiPen. The company snagged approval for its generic version of Mylan’s EpiPen Auto-Injector in August 2018.

February 19, 2019

·

2 min read

·

Alex Keown

Business

High Dose of Pfizer and Lilly Back Pain Drug Hits the Mark in Phase III Trial

When your back hurts, your whole body hurts. This morning, Pfizer and Eli Lilly reported positive results from its Phase III back pain treatment tanezumab.

February 19, 2019

·

2 min read

·

Alex Keown